iTeos Therapeutics (ITOS) Stock Forecast, Price Target & Predictions
ITOS Stock Forecast
iTeos Therapeutics stock forecast is as follows: an average price target of $37.67 (represents a 357.72% upside from ITOS’s last price of $8.23) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
ITOS Price Target
The average price target for iTeos Therapeutics (ITOS) is $37.67 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $46.00 to $31.00. This represents a potential 357.72% upside from ITOS's last price of $8.23.
ITOS Analyst Ratings
According to 3 Wall Street analysts, iTeos Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ITOS stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
iTeos Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 16, 2024 | Christopher Raymond | Raymond James | $36.00 | $16.70 | 115.57% | 337.42% |
| Aug 13, 2024 | Eva Fortea Verdejo | Wells Fargo | $31.00 | $14.50 | 113.79% | 276.67% |
| May 13, 2024 | Swayampakula Ramakanth | H.C. Wainwright | $46.00 | $17.44 | 163.76% | 458.93% |
The latest iTeos Therapeutics stock forecast, released on Sep 16, 2024 by Christopher Raymond from Raymond James, set a price target of $36.00, which represents a 115.57% increase from the stock price at the time of the forecast ($16.70), and a 337.42% increase from ITOS last price ($8.23).
iTeos Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 3 |
| Avg Price Target | - | $36.00 | $37.67 |
| Last Closing Price | $8.23 | $8.23 | $8.23 |
| Upside/Downside | -100.00% | 337.42% | 357.72% |
In the current month, the average price target of iTeos Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to iTeos Therapeutics's last price of $8.23. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 16, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 13, 2024 | Wells Fargo | - | Overweight | Initialise |
| May 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
iTeos Therapeutics's last stock rating was published by Piper Sandler on Sep 16, 2024. The company gave ITOS a "Overweight" rating, the same as its previous rate.
iTeos Therapeutics Financial Forecast
iTeos Therapeutics Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $12.60M | $53.91M | $19.49M | $41.72M | $152.52M | $240.50M | $104.27M | - |
| Avg Forecast | $14.89M | $4.62M | - | - | - | - | - | - | - | - | - | $9.35M | $800.00K | $800.00K | $1.00M | $12.47M | $6.90M | $41.16M | $41.64M | $85.56M | $63.30M | $85.45M | $6.50M | $3.91M |
| High Forecast | $14.89M | $4.62M | - | - | - | - | - | - | - | - | - | $9.35M | $800.00K | $800.00K | $1.00M | $12.47M | $6.90M | $41.16M | $41.64M | $85.56M | $63.30M | $85.45M | $6.50M | $3.91M |
| Low Forecast | $14.89M | $4.62M | - | - | - | - | - | - | - | - | - | $9.35M | $800.00K | $800.00K | $1.00M | $12.47M | $6.90M | $41.16M | $41.64M | $85.56M | $63.30M | $85.45M | $6.50M | $3.91M |
| # Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - | 1 | 1 | 3 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.83% | 1.31% | 0.47% | 0.49% | 2.41% | 2.81% | 16.04% | - |
iTeos Therapeutics's average Quarter revenue forecast for Dec 23 based on 2 analysts is $12.47M, with a low forecast of $12.47M, and a high forecast of $12.47M. ITOS's average Quarter revenue forecast represents a -1.01% decrease compared to the company's last Quarter revenue of $12.60M (Mar 23).
iTeos Therapeutics EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - | 1 | 1 | 3 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-23.63M | $18.99M | $-14.30M | $3.97M | $121.74M | $-32.01M | $72.59M | $-26.31M |
| Avg Forecast | $6.85M | $2.12M | - | - | - | - | - | - | - | - | - | $4.30M | $368.01K | $368.01K | $460.01K | $5.74M | $3.17M | $18.93M | $18.56M | $38.14M | $28.22M | $38.09M | $2.90M | $1.74M |
| High Forecast | $6.85M | $2.12M | - | - | - | - | - | - | - | - | - | $4.30M | $368.01K | $368.01K | $460.01K | $5.74M | $3.17M | $18.93M | $18.56M | $38.14M | $28.22M | $38.09M | $2.90M | $1.74M |
| Low Forecast | $6.85M | $2.12M | - | - | - | - | - | - | - | - | - | $4.30M | $368.01K | $368.01K | $460.01K | $5.74M | $3.17M | $18.93M | $18.56M | $38.14M | $28.22M | $38.09M | $2.90M | $1.74M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -7.44% | 1.00% | -0.77% | 0.10% | 4.31% | -0.84% | 25.05% | -15.11% |
1 analysts predict ITOS's average Quarter EBITDA for Mar 23 to be $3.17M, with a high of $3.17M and a low of $3.17M. This is -83.28% lower than iTeos Therapeutics's previous annual EBITDA (Dec 22) of $18.99M.
iTeos Therapeutics Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - | 1 | 1 | 3 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-15.55M | $20.45M | $991.00K | $5.63M | $69.58M | $-29.43M | $69.64M | $-26.46M |
| Avg Forecast | $-37.73M | $-47.41M | $-53.55M | $-57.67M | $-57.61M | $-57.10M | $-56.54M | $-55.86M | $-46.15M | $-50.12M | $-51.16M | $-48.40M | $-45.12M | $-50.53M | $-44.78M | $-44.57M | $-42.88M | $10.14M | $4.12M | $48.70M | $36.93M | $50.71M | $-20.91M | $-16.44M |
| High Forecast | $-37.73M | $-47.41M | $-53.55M | $-57.67M | $-57.61M | $-57.10M | $-56.54M | $-55.86M | $-46.15M | $-50.12M | $-51.16M | $-39.42M | $-36.33M | $-50.53M | $-44.78M | $-3.46M | $-42.88M | $10.14M | $4.12M | $50.13M | $44.32M | $50.71M | $-20.91M | $-16.44M |
| Low Forecast | $-37.73M | $-47.41M | $-53.55M | $-57.67M | $-57.61M | $-57.10M | $-56.54M | $-55.86M | $-46.15M | $-50.12M | $-51.16M | $-65.18M | $-56.97M | $-50.53M | $-44.78M | $-79.18M | $-42.88M | $10.14M | $4.12M | $47.27M | $29.55M | $50.71M | $-20.91M | $-16.44M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.36% | 2.02% | 0.24% | 0.12% | 1.88% | -0.58% | -3.33% | 1.61% |
iTeos Therapeutics's average Quarter net income forecast for Mar 23 is $-42.88M, with a range of $-42.88M to $-42.88M. ITOS's average Quarter net income forecast represents a -309.64% decrease compared to the company's last Quarter net income of $20.45M (Dec 22).
iTeos Therapeutics SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - | 1 | 1 | 3 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $11.93M | $11.10M | $10.76M | $11.47M | $10.62M | $-30.87M | $8.76M | $15.10M |
| Avg Forecast | $18.71M | $5.80M | - | - | - | - | - | - | - | - | - | $11.75M | $1.01M | $1.01M | $1.26M | $15.67M | $8.67M | $51.72M | $52.32M | $107.51M | $5.63M | $107.38M | $8.17M | $4.91M |
| High Forecast | $18.71M | $5.80M | - | - | - | - | - | - | - | - | - | $11.75M | $1.01M | $1.01M | $1.26M | $15.67M | $8.67M | $51.72M | $52.32M | $107.51M | $6.76M | $107.38M | $8.17M | $4.91M |
| Low Forecast | $18.71M | $5.80M | - | - | - | - | - | - | - | - | - | $11.75M | $1.01M | $1.01M | $1.26M | $15.67M | $8.67M | $51.72M | $52.32M | $107.51M | $4.51M | $107.38M | $8.17M | $4.91M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.38% | 0.21% | 0.21% | 0.11% | 1.88% | -0.29% | 1.07% | 3.08% |
iTeos Therapeutics's average Quarter SG&A projection for Dec 23 is $15.67M, based on 2 Wall Street analysts, with a range of $15.67M to $15.67M. The forecast indicates a 31.36% rise compared to ITOS last annual SG&A of $11.93M (Mar 23).
iTeos Therapeutics EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - | 1 | 1 | 3 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.44 | $-0.03 | $0.03 | $0.16 | $1.96 | $-0.84 | $1.98 | $-0.75 |
| Avg Forecast | $-0.87 | $-1.10 | $-1.24 | $-1.34 | $-1.34 | $-1.32 | $-1.31 | $-1.29 | $-1.07 | $-1.16 | $-1.19 | $-1.12 | $-1.05 | $-1.17 | $-1.04 | $-1.03 | $-0.99 | $0.23 | $0.10 | $1.23 | $0.82 | $1.28 | $-0.53 | $-0.41 |
| High Forecast | $-0.87 | $-1.10 | $-1.24 | $-1.34 | $-1.34 | $-1.32 | $-1.31 | $-1.29 | $-1.07 | $-1.16 | $-1.19 | $-0.91 | $-0.84 | $-1.17 | $-1.04 | $-0.08 | $-0.99 | $0.23 | $0.10 | $1.26 | $0.82 | $1.28 | $-0.53 | $-0.41 |
| Low Forecast | $-0.87 | $-1.10 | $-1.24 | $-1.34 | $-1.34 | $-1.32 | $-1.31 | $-1.29 | $-1.07 | $-1.16 | $-1.19 | $-1.51 | $-1.32 | $-1.17 | $-1.04 | $-1.84 | $-0.99 | $0.23 | $0.10 | $1.19 | $0.82 | $1.28 | $-0.53 | $-0.41 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.44% | -0.11% | 0.29% | 0.13% | 2.39% | -0.66% | -3.76% | 1.81% |
According to 1 Wall Street analysts, iTeos Therapeutics's projected average Quarter EPS for Dec 22 is $0.23, with a low estimate of $0.23 and a high estimate of $0.23. This represents a 683.33% increase compared to ITOS previous annual EPS of $0.03 (Sep 22).
iTeos Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ITOS | iTeos Therapeutics | $8.23 | $37.67 | 357.72% | Buy |
| SANA | Sana Bio | $2.42 | $8.00 | 230.58% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.40 | $7.00 | 191.67% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.31 | $38.80 | 191.51% | Buy |
| APLS | Apellis Pharmaceuticals | $26.27 | $74.50 | 183.59% | Buy |
| TCRX | TScan Therapeutics | $4.41 | $12.00 | 172.11% | Buy |
| ERAS | Erasca | $2.67 | $7.00 | 162.17% | Buy |
| TERN | Terns Pharmaceuticals | $6.17 | $14.25 | 130.96% | Buy |
| ANNX | Annexon | $6.12 | $14.00 | 128.76% | Buy |
| DSGN | Design Therapeutics | $5.80 | $9.67 | 66.72% | Buy |
| MLTX | MoonLake Immunotherapeutics | $48.83 | $79.33 | 62.46% | Buy |
| BPMC | Blueprint Medicines | $88.69 | $109.71 | 23.70% | Buy |
| KYMR | Kymera Therapeutics | $41.96 | $51.50 | 22.74% | Buy |
| AMLX | Amylyx Pharmaceuticals | $4.76 | $5.33 | 11.97% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $55.13 | $60.63 | 9.98% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |